



## DATASHEET

# PrecisIOn™

## hKv7.2/hKv7.3-CHO

# Recombinant Cell Line

CATALOG # CYL3059

REVISION # M05

### ORDERING INFORMATION AND TECHNICAL SERVICES

Millipore (UK) Ltd  
6-7 Technopark  
Cambridge CB5 8PB  
UK

Tel: +44 (0) 1223 508191

Fax: +44 (0) 1223 508198


### CUSTOMER SERVICES

UK: 0800 0190 333


US: 800 437 7500




GPCR



Ion Channels



Kinase /  
Phosphatase



Safety & Toxicity  
Profiling

**Product description:**

Recombinant CHO-K1 cell line co-expressing the human Kv7.2 (voltage-gated potassium channel, KQT-like subfamily, member 2 (KCNQ2), accession number Y15065) and the human Kv7.3 (voltage-gated potassium channel, KQT-like subfamily, member 3 (KCNQ3), accession number NM\_004519).

**Format:**

2 x 1 ml aliquots containing  $1.58 \times 10^6$  cells/ml in 7.5% DMSO at passage 10.

**Mycoplasma Testing:**

The cell line has been screened using the PCR Mycoplasma Test Kit (MDBiosciences) to confirm the absence of Mycoplasma species.

**Functional Validation:**

hKv7.2/hKv7.3 (KCNQ2/KCNQ3) channels have been selectively expressed in a CHO-K1 cell line and characterized in terms of their biophysical and pharmacological properties using whole-cell and perforated patch clamp techniques and IonWorks™ Quattro.

The currents displayed all the hallmarks for selective expression of Kv7.x channels such as a relatively negative threshold of activation, the absence of any inactivation and slow activation/deactivation kinetics. The current/voltage relationship was linear and the mean outward current at 0 mV was  $2.2 \pm 0.3$  nA (n=3). Thus this cell line has an ideal level of functional expression for both manual and automated patch clamp applications.

Using perforated patch clamp techniques the currents were found to be dose-dependently blocked by TEA in the appropriate range for expression of Kv7.2/Kv7.3 channels (approximately 58% inhibition at 3 mM). The effects of the selective Kv7.x blockers linopirdine and XE991 were also assessed using IonWorks™ Quattro and the  $IC_{50}$  values obtained were similar to published values; around 9  $\mu$ M and 2  $\mu$ M respectively.

IonWorks™ Quattro was also used to examine the effects of the hKv7.2/hKv7.3 opener retigabine. Retigabine dose-dependently increased the current amplitude in response to voltage steps to either -50 mV or -30 mV.  $EC_{50}$  values were approximately 2 and 1  $\mu$ M respectively.

Channel expression, monitored using IonWorks™ HT, is robust over at least 40 passages. For example 96% of cells expressed outward current >500 pA at passage 40 (n=170) with a mean current amplitude of  $2 \pm 0.06$  nA.

**Recommended culture Conditions:**

Recommended culture conditions and standard operating procedure are provided with the product.

**Licensing Statements**

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242, USA.

The bovine growth hormone (bgh) polyadenylation signal and its use in the expression of recombinant proteins is covered by claims listed in U.S. Patent No. 5,122,458, EU Patent No. 0 173 552 and Japanese Patent No. 1955752 (collectively "CLAIMED DNA and/or CLAIMED CELLS") owned and licensed to Millipore (formerly Upstate Biotechnology Inc.) by Research Corporation Technologies, Inc., 101 North Wilmot Road, Suite 600, Tucson, AZ 85711-3335 ("RCT").

Use of this technology is restricted to research purposes only. The purchased/licensed cell line and all bacteria, phages and plasmids derived from this cell line, in whole or in part, and all proteins expressed from the cell line shall be used for research uses only. "Research purposes" means uses directed to the identification of useful recombinant proteins and the investigation of the recombinant expression of proteins. In no event shall research use include any of the following: any use in humans of a CLAIMED DNA or CLAIMED CELL; any use in human or protein expression or other substance expressed or made at any stage of its production that use the CLAIMED DNA or a CLAIMED CELL; or any use in which a CLAIMED DNA or CLAIMED CELL would be sold or transferred to a third party. No license, other than research use, is expressed or implied by the purchase/license of the cell line. By accepting or using Millipore's cell line product, you agree to be bound for the following use/license restrictions:

This product enables the user which purchased/licensed it to use the cDNA construct for research purposes only and additional restrictions apply to commercial uses of the cell line. Such commercial uses, include uses such as resale, bulk preparation of proteins encoding the cDNA, application of the product with transgenic animals or human experiments, or use in screening or drug development. All commercial uses require a separate written license from Millipore Corporation and may require additional licenses from RCT, whose contact is Dr. Jennifer Tonzello, phone, +001 520-748-4441.

IonWorks™ HT and IonWorks™ Quattro are trademarks of Molecular Devices Corporation

**Introduction:**

The predominant heteromultimer responsible for the neuronal M-current is now known to consist of hKv7.2 (KCNQ2) and hKv7.3 (KCNQ3) subunits (Wang *et al.*, 1998). This current was first described in bullfrog sympathetic neurons (Brown and Adams, 1980) and subsequently found to be distributed in various central and peripheral neurons. It has a fundamental role in determining the sub-threshold excitability of neurons and their responsiveness to synaptic input (Cooper, 2001 and Jentsch, 2000). This is highlighted by the observation that mutations that reduce the number of functional Kv7.2/Kv7.3 channels can result in an inherited form of epilepsy (Chung *et al.*, 2006). Since these channels have such an important role in regulating neuronal excitability they have become important targets for the treatment of epilepsy and pain.

**Electrophysiological Properties of the hKv7.2/hKv7.3 Current.****Conventional Whole-Cell Patch Clamp Electrophysiology.****hKv7.2/hKv7.3 kinetics:**


hKv7.x channels have a number of characteristic electrophysiological properties which, taken together, make them distinct from other Kv channels. These are a relatively negative threshold of activation (-50/-60 mV), slow activation and deactivation kinetics and the absence of inactivation. These distinctive kinetic properties are illustrated in **Figure 1A**. The membrane voltage was stepped from a holding potential of -60 mV to -30 mV which evoked, after a significant delay (**Figure 1A**, arrow), a slowly activating outward current that was sustained for the duration of the depolarizing pulse. The delay in onset and sustained activation are typical of both the native M-current and Kv7.2/Kv7.3 expressed in mammalian cell lines (Wang *et al.*, 1998 and Adams and Brown, 1982). Stepping the membrane voltage back to -60 mV first caused an instantaneous reduction in the outward current, reflecting the reduced driving force for potassium through open channels activated at -30 mV, followed by a slowly deactivating tail current. Inverting the voltage protocol by using a holding potential of -30 mV and stepping to -60 mV, produced the expected current trace for non-inactivating M/Kv7.2/Kv7.3 currents reported previously (Adams and Brown, 1982). For example, holding the potential at -30 mV produced a large non-inactivating outward current (around 1 nA in **Figure 1A**) that deactivated slowly at -60 mV after the instantaneous current. Subsequently returning to -30 mV after all the channels had closed at -60 mV, lead to re-activation of the current along the expected sigmoidal time course, after the initial delay.

To further characterise the time course of deactivation, the voltage was first stepped to -30 mV for 2 s to fully activate the channels prior to returning to various test potentials (**Figure 1B**). The time course of current deactivation at each test potential was measured by fitting the current to an exponential. Time constants for the fits were  $73 \pm 9.5$  ms,  $113 \pm 20$  ms,  $172 \pm 29$  ms and  $205 \pm 37$  ms for -70 mV, -60 mV, -50 mV and -40 mV respectively (n =3). These values are similar to values obtained in sympathetic neurons, e.g. around 44 ms and 150 ms at -70 mV and -40 mV respectively (Adams and Brown, 1982).

**Figure 1. Kinetics of hKv7.2/hKv7.3 currents.**

**A.** hKv7.2/hKv7.3 currents were either opened by a depolarizing step from -60 mV to -30 mV (upper panel) or closed by a hyperpolarizing step from -30 mV to -60 mV (lower panel).

**B.** The time course of current deactivation was assessed by stepping the membrane voltage from -30 mV to various negative potentials (lower panel). Decaying currents (upper panel) were fitted with exponentials.




**Current-voltage (I/V) relationship:**

The I/V relationship was examined by stepping from a holding potential of -80 mV to increasingly depolarized voltages for 2 s; -80 mV to +50 mV in 10 mV increments every 10 s (**Figure 2**). As described above, currents activated subsequent to a delay and slowly reached a sustained level during the depolarizing pulse, with no inactivation (**Figure 2A**). The I/V plot was obtained by measuring the amplitude of the current at the end of the depolarizing step and plotting these values against the step voltage (**Figure 2B**). The threshold of activation was quite negative, between -50 mV and -40 mV, which is another distinguishing feature of this K<sup>+</sup> channel (see above). Similar to previously published data (Main *et al.*, 2000, Zhang *et al.*, 2003) the I/V relationship was linear with a mean sustained outward current of  $2.2 \pm 0.3$  nA (n=3) at 0 mV.

**Figure 2. I/V relationship of hKv7.2/hKv7.3 currents.**

**A.** Currents (upper panel) were evoked by 2000 ms depolarising voltage pulses stepped in 10 mV increments from -80 mV to +50 mV from a holding potential of -80 mV once every 10 seconds (lower panel). The green dotted line indicates zero current level.


**B** The steady state current amplitudes elicited by the voltage protocol shown in **A** were normalised to the current evoked by the +50 mV voltage step for each cell. The mean data (n=3) is shown plotted against the step potential (mV).



Kv7.x currents, unlike many other Kv channels have a marked tendency to 'run-down' in whole-cell mode. The rate and extent of this 'run-down' varies from cell to cell but can be largely removed by employing the perforated patch technique (Guo and Schofield, 2002 and Hadley *et al.*, 2000). This is illustrated in **Figure 3** where hKv7.2/hKv7.3 currents were evoked by repetitive pulses to 0 mV every 10 s. The amplitude of each pulse is plotted against pulse number from the time of either establishing whole cell (solid circles) or perforated patch with an access resistance <15 MΩ (open circles). The current has a consistent amplitude of around 2 nA in the perforated patch configuration but 'runs down' in whole-cell mode. Consequently it is recommended that wherever possible the perforated patch technique is employed when using this cell line.

**Figure 3. I/V relationship of hKv7.2/hKv7.3 currents.**

hKv7.2/hKv7.3 currents were evoked every 10 s by voltage steps from a holding potential of -80 mV to 0 mV. Each evoked current was plotted against pulse number from the time of establishing whole-cell (solid circles) or the perforated patch configuration (open circles).



**Pharmacology - Tetraethylammonium chloride (TEA).****Manual Patch Clamp (Perforated Patch Configuration).**



TEA has previously been used as a pharmacological tool to discriminate between the various combinations Kv7 subunits (Wang *et al.*, 1998, Hadley *et al.*, 2000). The differential sensitivity is conferred by the variable presence of tyrosine, threonine or valine in the upper pore region, downstream from the GYG selectivity sequence. Pertinent to this study it was reported (Hadley *et al.*, 2000) that in a recombinant CHO cell line homomeric Kv7.2 channels are the most sensitive ( $IC_{50} = 0.3$  mM), Kv7.3 channels are relatively insensitive ( $IC_{50} > 30$  mM) whereas heteromultimers of Kv7.2/Kv7.3 channels have an intermediate sensitivity ( $IC_{50} \sim 4$  mM). Consistent with the presence of heteromultimers, bath application of 0.3 mM, 3 mM and 30 mM TEA blocked currents by  $28 \pm 2.9\%$  ( $n = 5$ ),  $57.5 \pm 8\%$  ( $n = 6$ ) and  $88.3 \pm 5.5\%$  ( $n = 6$ ) respectively (**Figure 4**).

**Figure 4. Effect of TEA on hKv7.2/hKv7.3 currents.**


**A.** Cells were pulsed to a potential of 0 mV for 2 seconds from a holding potential of -80 mV and repeated every 10 seconds. Once stable hKv7.2/hKv7.3 current amplitudes at 0 mV were achieved under control conditions, increasing doses of TEA were cumulatively applied to the cell, allowing each concentration to achieve a stable reduction in current amplitude prior to addition of a subsequent dose. Outward current measured at the end of the depolarizing pulse to 0 mV is plotted against time.

**B.** Typical current records obtained prior to addition (Control, black trace) and after 0.3 mM (red trace), 3 mM (blue trace) and 30 mM (green trace) TEA. The blue dotted line is the zero current level.

**C.** The mean percent inhibition relative to the control amplitude prior to addition for each concentration of TEA is shown ( $n = 5-6$ ).

**A****B**

**C**




**Pharmacology – Linopirdine and XE991.****IonWorks™ Quattro (Population Patch Configuration).**

The cognitive enhancer linopirdine and the more potent analogue, XE991 have frequently been used in the characterization of Kv7.x channels. Reported IC<sub>50</sub> values for linopirdine for the native M-current range between 2–7 μM (Passmore *et al.*, 2003, Wang *et al.*, 1998, Costa and Brown, 1997; Lamas *et al.*, 1997) and for Kv7.2/Kv7.3 currents around 4 μM (Wang *et al.*, 1998). Consistent with these findings linopirdine dose-dependently blocked hKv7.2/hKv7.3 currents with an estimated IC<sub>50</sub> of 8.5 μM (**Figure 5A**). Reported IC<sub>50</sub> values for XE991 range between 0.3-1 μM for the native M-current (Passmore *et al.*, 2003; Wang *et al.*, 1998) and 0.6 μM for Kv7.2/Kv7.3 currents (Wang *et al.*, 1998). Here, the IC<sub>50</sub> value for XE991 block was around 2.2 μM (**Figure 5B**). This slight discrepancy with previous reports (2-4 fold) is most likely due to this method of recording.

**Figure 5. Effect of Linopirdine and XE991 on hKv7.2/hKv7.3 currents.**

The effect of a 10 min incubation of various concentrations of either linopirdine (**A**) or XE991 (**B**) was assessed on the amplitude of hKv7.2/hKv7.3 currents using IonWorks™ Quattro automated electrophysiology. Each data point represents the mean of 12 cells.




**Pharmacology – Retigabine:****IonWorks™ Quattro (Population Patch Configuration).**

Retigabine is currently in late Phase III clinical trials (May 2008) for drug-resistant epilepsy and has been shown mediate many of its anticonvulsant effects through the opening of hKv7.2/hKv7.3 channels (Main *et al.*, 2000, Wickenden *et al.*, 2000). Retigabine shifts the  $V_{1/2}$  of activation in the hyperpolarizing direction so that larger currents result in response to negative voltage steps of a constant amplitude. This is illustrated in **Figure 6** using IonWorks™ Quattro, measuring the amplitude of hKv7.2/hKv7.3 currents before and after various concentrations of retigabine at either -50 mV (**A**) or -30 mV (**B**). At -50 mV the currents are relatively small (0.2–0.4 nA) since this is around the threshold of activation (**Figure 2**). However, addition of retigabine lead to a dose-dependent increase in the amplitude of the current, the maximal effect occurring at 10  $\mu$ M where the current was about 7-fold greater than the amplitude recorded under control conditions. A logistic fit of the data gave an estimate of the  $EC_{50}$  value for this effect of around 2  $\mu$ M. Similar data was obtained at -30 mV ( $EC_{50} \sim 1 \mu$ M).  $EC_{50}$  values reported here are slightly greater than Wickenden *et al.*, 2000, who measured the effect of retigabine on the amplitude of the current evoked by a voltage step to -40 mV ( $EC_{50} = 0.34 \mu$ M). This difference probably reflects differences in methodology (Wickenden *et al.*, 2000 used manual patch clamp techniques) rather than a genuine difference in sensitivity and demonstrates that classical potassium channel openers can be reliably detected with this cell line using IonWorks™ Quattro.

**Figure 6. Effect of Retigabine on hKv7.2/hKv7.3 currents.**

The effect of a 10 min incubation of various concentrations of retigabine on the amplitude of hKv7.2/hKv7.3 currents evoked by a voltage step to either -50 mV (A) or -30 mV (B). Each data point represents the mean of 5-8 cells.



**Stability of hKv7.2/hKv7.3-CHO K1 Cell Line.**


**IonWorks™ HT Electrophysiology.**

The hKv7.2/hKv7.3-CHO K1 cell line has stable expression for >40 passages.

Functional channel expression, defined as cells expressing potassium current of > 500 pA, was monitored using IonWorks™ HT. This data and the mean current amplitude is shown in **Figure 7**. Sealing data is shown in **Figure 8**.


**Figure 7. Stability of expression over passage.**

The upper panel shows the percentage of cells expressing a mean peak current >500 pA at 0 mV at cell passages 10, 19, 27, 31, 37 and 40. The lower panel shows the mean current amplitude (mean ± SEM, red circles) and the number of cells (numbers above red circles - out of 64 cells for passage 10 and out of 192 cells for all other passages).




**Figure 8. Sealing rates over passage.**


The percentage of cells sealing (defined by a seal resistance of >50 MΩ).



**Vectors:**



Polylinker: CMV-BamHI-NotI-XhoI- AscI-NdeI-ClaI-HpaI-**hKv7.2**-EcoRI-IRES-*neo*



Polylinker: CMV-KpnI-SacI-BamHI-hKv7.3-BstXI-IVS-NotI-IRES-hyg

**hKv7.2 Sequence:**

The sequence of hKv7.2 used to create this stable cell line contains the following 2 silent base changes with respect the GenBank accession number Y15065.

Bases 2254-2256: ACC-ACG (Thr - silent)  
Bases 2380-2382: GCG-GCT (Ala - silent)

**hKv7.3 Sequence (Accession Number NM\_004519):**

**References:**

- Adams, P. R., Brown, D. A., and Constanti, A. (1982) M-currents and other potassium currents in bullfrog sympathetic neurones *J Physiol* **330**, 537-572.
- Brown, D. A., and Adams, P. R. (1980) Muscarinic suppression of a novel voltage-sensitive K<sup>+</sup> current in a vertebrate neurone *Nature* **283**(5748), 673-676.
- Chung, H. J., Jan, Y. N., and Jan, L. Y. (2006) Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains *Proc Natl Acad Sci U S A* **103**(23), 8870-8875.
- Cooper, E. C. (2001) Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs *Epilepsia* **42 Suppl 5**, 49-54.
- Costa, A. M., and Brown, B. S. (1997) Inhibition of M-current in cultured rat superior cervical ganglia by linopirdine: mechanism of action studies *Neuropharmacology* **36**(11-12), 1747-1753.
- Guo, J., and Schofield, G. G. (2002) Histamine inhibits KCNQ2/KCNQ3 channel current via recombinant histamine H(1) receptors *Neurosci Lett* **328**(3), 285-288.
- Hadley, J. K., Noda, M., Selyanko, A. A., Wood, I. C., Abogadie, F. C., and Brown, D. A. (2000) Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels *Br J Pharmacol* **129**(3), 413-415.
- Jentsch, T. J. (2000) Neuronal KCNQ potassium channels: physiology and role in disease *Nature reviews* **1**(1), 21-30.
- Lamas, J. A., Selyanko, A. A., and Brown, D. A. (1997) Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type potassium currents (IK(M)) and some other voltage- and ligand-gated membrane currents in rat sympathetic neurons *Eur J Neurosci* **9**(3), 605-616.
- Main, M. J., Cryan, J. E., Dupere, J. R., Cox, B., Clare, J. J., and Burbidge, S. A. (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine *Molecular pharmacology* **58**(2), 253-262.
- Passmore, G. M., Selyanko, A. A., Mistry, M., Al-Qatari, M., Marsh, S. J., Matthews, E. A., Dickenson, A. H., Brown, T. A., Burbidge, S. A., Main, M., and Brown, D. A. (2003) KCNQ/M currents in sensory neurons: significance for pain therapy *J Neurosci* **23**(18), 7227-7236.
- Wang, H. S., Pan, Z., Shi, W., Brown, B. S., Wymore, R. S., Cohen, I. S., Dixon, J. E., and McKinnon, D. (1998) KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel *Science* **282**(5395), 1890-1893.
- Wickenden AD, Yu W, Zou A, Jegla T & Wagoner PK. (2000). Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. *Molecular pharmacology* **58**, 591-600.
- Zhang, H., Craciun, L. C., Mirshahi, T., Rohacs, T., Lopes, C. M., Jin, T., and Logothetis, D. E. (2003) PIP(2) activates KCNQ channels, and its hydrolysis underlies receptor-mediated inhibition of M currents *Neuron* **37**(6), 963-975.